Samenvatting
A prevalent eukaryotic N6-methyladensosine (m6A) post-transcriptional mark can be “erased” by the m6A demethylase FTO, which is commonly deregulated in acute myeloid leukemia (AML). In this issue of Cancer Cell, Huang et al. design small-molecule FTO inhibitors, FB23 and FB23-2, and demonstrate their potent inhibitory impact in AML models.
| Originele taal-2 | Engels |
|---|---|
| Pagina's (van-tot) | 540-541 |
| Aantal pagina's | 2 |
| Tijdschrift | Cancer Cell |
| Volume | 35 |
| Nummer van het tijdschrift | 4 |
| DOI's | |
| Status | Gepubliceerd - 15 apr. 2019 |
| Extern gepubliceerd | Ja |